< Founder and Chairman Yigal Erlich (left), President Kwang Hyung Lee, and Head of Asia Pacific Won-Jae Lee (right) >
KAIST has joined hands with Israeli venture capital investor Yozma Group to help campus-based startups grow and build success. The two signed a memorandum of understanding (MOU) on joint technology value creation initiatives at the signing ceremony that was held at KAIST’s main campus in Daejeon on April 8.
Under the MOU, Yozma Group will make investments and implement acceleration programs for startups established by KAIST professors, graduates, and students, as well as those invested in by the university.
Yozma Group already launched a $70 million fund to help grow companies in Korea and Israel. Yozma Group will use the fund as well as its global acceleration know-how and network of over 400 R&D centers across Israel to help promising KAIST startups enter overseas markets.
Moreover, Yozma Group also plans to discover and support KAIST startups that need technology from the Weizmann Institute of Science, Israel’s leading multidisciplinary basic research institution in natural and exact sciences.
KAIST is also in talks to locate Yozma Group’s branch office on the university’s campus to ensure seamless collaborations.
KAIST President Kwang Hyung Lee explained to Yozma Group’s Founder and Chairman Yigal Erlich and Head of Asia Pacific Won-Jae Lee at the MOU signing ceremony that “startup and technology commercialization are the crucial areas where KAIST will make innovations.”
“Cooperation with Yozma Group will help KAIST startups transform their ideas and technologies into real businesses and build a global presence,” he added.
Yozma Group started as Yozma Fund, created in conjunction with the Israeli government in 1993 to support the globalization of Israeli startups and to foster the growth of Israel’s venture capital industry. The Fund, which was privatized in 1998, has supported 97 Israeli tech ventures joining the Nasdaq, leading Israel to become a global innovation hub that has the third-most companies listed on the Nasdaq.
(END)
< (From left) KAIST President Kwang-Hyung Lee and Merck CEO Matthias Heinzel > KAIST (President Kwang-Hyung Lee) signed a Memorandum of Understanding (MOU) with Merck Life Science (CEO Matthias Heinzel) on May 29 to foster innovation and technology creation in advanced biotechnology. Since May of last year, the two institutions have been discussing multidimensional innovation programs and will now focus on industry-academia cooperation to tackle bioindustry challenges with this MOU a
2024-05-30< (From left) Jong-Soo Lee, Executive Vice President at Hyundai Motor, Sang-Yup Lee, Senior Vice President for Research at KAIST > The ‘Hyundai Motor Group-KAIST On-Chip LiDAR Joint Research Lab’ was opened at KAIST’s main campus in Daejeon to develop LiDAR sensors for advanced autonomous vehicles. The joint research lab aims to develop high-performance and compact on-chip sensors and new signal detection technology, which are essential in the increasingly compe
2024-02-27Representing Korean Robotics at Sea: KAIST’s 26-month strife rewarded Team KAIST placed among top two at MBZIRC Maritime Grand Challenge - Team KAIST, composed of students from the labs of Professor Jinwhan Kim of the Department of Mechanical Engineering and Professor Hyunchul Shim of the School of Electrical and Engineering, came through the challenge as the first runner-up winning the prize money totaling up to $650,000 (KRW 860 million). - Successfully led the autonomous collaborat
2024-02-09< Photo 1. 2023 KAIST Tech Fair in New York > KAIST (President Kwang-Hyung Lee) announced on the 11th that it will hold the ‘2023 KAIST Tech Fair in New York’ at the Kimmel Center at New York University in Manhattan, USA, on the 22nd of this month. It is an event designed to be the starting point for KAIST to expand its startup ecosystem into the global stage, and it is to attract investments and secure global customers in New York by demonstrating the technological value
2023-09-11KAIST (President Kwang Hyung Lee) announced on the 29th that it has signed MOUs with Massachusetts General Hospital, a founding member of the Mass General Brigham health care system and a world-class research-oriented hospital, and Moderna, a biotechnology company that developed a COVID-19 vaccine at the Langham Hotel in Boston, MA, USA on the morning of April 28th (local time). The signing ceremony was attended by officials from each institution joined by others headed by Minister LEE Young of
2023-04-29